Compare CLDX & CSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLDX | CSQ |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | 1995 | 2004 |
| Metric | CLDX | CSQ |
|---|---|---|
| Price | $27.73 | $19.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $63.07 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 191.1K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,743,000.00 | N/A |
| Revenue This Year | $19.74 | N/A |
| Revenue Next Year | $438.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $22.10 | $16.41 |
| 52 Week High | $45.14 | $21.17 |
| Indicator | CLDX | CSQ |
|---|---|---|
| Relative Strength Index (RSI) | 29.14 | 34.60 |
| Support Level | $22.39 | $19.50 |
| Resistance Level | $32.16 | $19.83 |
| Average True Range (ATR) | 1.26 | 0.31 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 1.72 | 6.06 |
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.